Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of NADPH in preparation of drugs used for treating heart diseases

A technology for heart disease and medicine, which is applied in the application field of NADPH in the preparation of medicine for treating heart disease, and can solve the problems of reducing pentose metabolic activity, aggravating myocardial injury, increasing glycolysis and the like

Inactive Publication Date: 2015-08-19
SUZHOU RENBEN PHARMA
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The function of TIGAR is to inhibit glycolysis and activate the pentose bypass, which produces two metabolites: -NADPH and pentose 5-phosphate. Therefore, the effect of knocking out TIGAR increases glycolysis and decreases The activity of pentose metabolism, and the inhibition of pentose pathway means that NADPH is reduced, so it can be inferred that NADPH has an aggravating effect on myocardial injury. Therefore, there is no research on the application of NADPH in the treatment of heart diseases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of NADPH in preparation of drugs used for treating heart diseases
  • Application of NADPH in preparation of drugs used for treating heart diseases
  • Application of NADPH in preparation of drugs used for treating heart diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Embodiment 1 contains the capsule of NADPH

[0021] The capsule of the present embodiment comprises following composition:

[0022] NADPH 20g; suspending agent microcrystalline cellulose 60g; preservative tert-butyl-4-hydroxyanisole 0.04g; lubricant magnesium stearate 2g; filler lactose added to 200g.

[0023] Its preparation method comprises the following steps:

[0024] Weigh the NADPH and various pharmaceutical excipients in the above prescription amount, mix them evenly, pass through a 60-mesh sieve three times, and put them into capsules.

[0025] The conventional excipients used in the medicine include but are not limited to one or a mixture of fillers, disintegrants, lubricants, binders, flavoring agents, suspending agents, and preservatives.

[0026] Specifically, the filler can also be replaced with a mixture of one or more of pregelatinized starch, mannitol, chitin, microcrystalline cellulose, and sucrose;

[0027] The disintegrant can also be replaced by o...

experiment example 1

[0037] Experimental Example 1 The protective effect of exogenous NADPH on primary cultured endothelial cells HUVEC

[0038] (1) Experimental materials:

[0039] The primary cultured endothelial cells HUVEC cells used in the experiment were purchased from ATCC cell bank in the United States. Cryopreservation conditions: 2ml cryopreservation tubes, 1.6 million cells per tube, containing 70% high glucose DMEM, 20% domestic fetal bovine serum, 10% DMSO.

[0040] (2) Experimental plan:

[0041] Endothelial cell HUVEC culture: culture conditions: 37°C (5% CO2, 95% air), saturated humidity, high-sugar DMEM medium, medium containing 100U penicillin and 100U streptomycin per liter; 10% domestic fetal bovine serum; The cells were grown to about 80-90% confluence, digested with trypsin-EDTA solution and then passaged, passage density: 5×10 5 Each bottle is passaged every 2-3 days; take the logarithmic growth of HUVEC cells, add an appropriate amount of trypsin-EDTA digestion solution to...

experiment example 2

[0045] Experimental Example 2 Prophylactic administration of NADPH to reduce blood-brain barrier-related immune cell responses after brain injury

[0046] (1) Experimental materials

[0047] Clean-grade male ICR mice, weighing 23-28 g, were provided by the Experimental Animal Center of Soochow University, experimental animal production license number: XCYK (Su) 2002-2008, experimental animal use license number: SYXK (Su) 2002-0037. C57BL6 and Tg(Itgax-Venus)1Mnz mice, weighing 22-27g, are male. Tg(Itgax-Venus)1Mnz mice are products of MGI Company. The mice are positive for CD11c-eYFP and are used to study the involvement of dendritic cells in the immune response after brain injury. The room temperature is 22°C, the humidity is 50-60%, the ventilation is good, artificial day and night (12h / 12h), free to eat and drink. Before the experiment, the male mice were acclimatized in the breeding environment for 2 days. Dextran-Texas (Red): product of Invitrogen Company, NADPH reagen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of NADPH in preparation of drugs used for treating heart diseases. Research results show that NADPH can protect vascular endothelial cells, maintain normal vascular permeability and reduce myocardial damage; through research on administration of exogenous NADPH for treatment of myocardial damage, novel application NADPH in treatment of heart diseases is found out.

Description

technical field [0001] The invention relates to a new indication of NADPH, specifically the application of NADPH in the preparation of medicines for treating heart disease. Background technique [0002] Cardiovascular and cerebrovascular diseases refer to diseases of the heart and cerebrovascular. Cardiovascular and cerebrovascular diseases have the characteristics of "high morbidity, high mortality, high disability rate, high recurrence rate, and many complications" ("four high and one high"), and have become a heavy burden on global health care and health resources , is the number one enemy of the second health revolution. At present, there are more than 270 million patients with cardiovascular and cerebrovascular diseases in my country. Especially after my country enters an aging society, the incidence of cardiovascular and cerebrovascular diseases is still increasing. important task in the medical field. The pathogenesis of cardio-cerebral ischemic diseases is very com...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7084A61P9/10A61P9/00
CPCA61K31/7084A61P9/00A61P9/10
Inventor 秦正红李梅韩峰
Owner SUZHOU RENBEN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com